The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Last week’s settlement that would see Purdue Pharma and its owners, the Sackler family, pay $7.4 billion to resolve lawsuits filed by state and local governments across the country is ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.

Multiple states have reached a tentative new agreement with the Sackler family, who made billions of dollars marketing OxyContin, the drug that set off the U.S. opioid crisis. New York State Attorney ...

Suzetrigine is an orally available pain signal inhibitor that selectively targets the NaV1.8 voltage-gated sodium channel, a genetically validated pain target found on peripheral neurons. NaV1.8 is ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...

Purdue’s Agricultural Economics Department covers a wide array of issues from development, trade, macroeconomics policy implications, agribusiness, production and consumption all the way to ...

When the White House budget office released a memo this week that instructed all federal agencies to cease spending on any ...

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 1,01,355.31 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...